Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DDAVP (NEEDS NO REFRIGERATION) vs PITRESSIN TANNATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.
Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.
Central diabetes insipidus,Nocturnal enuresis,Hemophilia A with factor VIII levels >5%,Von Willebrand disease (type I)
Diabetes insipidus (central),Nocturnal enuresis (off-label),Variceal bleeding (off-label)
1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.
0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.
Terminal elimination half-life is 1.5-3 hours for intravenous and oral routes; increased to 3-5 hours in patients with renal impairment.
Terminal elimination half-life approximately 15 minutes (range 10–20 minutes). Clinically, due to rapid clearance, effects are short-lived; continuous infusion or depot formulations are required for sustained effect.
Desmopressin undergoes limited hepatic metabolism via reduction of the disulfide bond; primarily excreted unchanged in urine.
Metabolized primarily by the liver and kidneys via peptidases, with a half-life of about 10-20 minutes for vasopressin itself; the tannate formulation prolongs absorption.
Primarily renal (approximately 60-70% excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal elimination negligible (<5%).
Low; approximately 0-1% bound to plasma proteins; negligible binding to albumin or other proteins.
Negligible (<1%); mainly bound to plasma proteins primarily vasopressin-binding proteins and albumin, but binding is not clinically significant.
Approximately 0.3-0.5 L/kg; reflects distribution primarily into extracellular fluid with limited tissue penetration.
Approximately 0.1 L/kg (range 0.08–0.12 L/kg). This low Vd indicates minimal tissue distribution, consistent with its predominant plasma volume confinement and renal clearance.
Oral: ~0.5% (range 0.1-1%) due to extensive gastrointestinal degradation; Intranasal: ~3-5% (range 2-10%); Intravenous: 100%.
Intramuscular oil suspension: nearly 100% but with slow release. Subcutaneous: approximately 10–15% due to hydrolysis at injection site. Oral: negligible (<1%) due to enzymatic degradation.
No dose adjustment required for GFR >30 m L/min; for GFR 10-30 m L/min, reduce dose by 50%; avoid use if GFR <10 m L/min.
Not significantly renally excreted; no specific dose adjustment recommended based on GFR.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential fluid retention.
No specific guidelines; use with caution in hepatic impairment due to potential fluid imbalance.
Diabetes insipidus: oral 0.05 mg/kg/day in 2 divided doses; intranasal 5-30 mcg/day; IV/SC 0.1-1 mcg/day. Hemophilia A: IV 0.3 mcg/kg every 12-24 hours for 2-3 days.
0.1-0.3 m L (1-3 units) intramuscularly or subcutaneously, with dose adjusted based on response; monitor urine output and serum sodium.
Start at low end of dosing range due to increased risk of hyponatremia and fluid overload; monitor serum sodium closely.
Start at lower end of dosing range (0.5 m L initially) due to increased risk of electrolyte disturbances and comorbid conditions; monitor serum sodium and fluid status closely.
No FDA black box warning.
None.
Hyponatremia and water intoxication, especially in patients with fluid/electrolyte imbalances or those on medications increasing ADH effect,Increased risk of thrombotic events (e.g., stroke, MI) in predisposed patients,Fluid restriction advised to prevent hyponatremia
Hyponatremia and water intoxication; cardiac effects including arrhythmias and ischemia; mesenteric ischemia; hypersensitivity reactions; use with caution in patients with coronary artery disease, hypertension, or renal impairment.
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Type IIB von Willebrand disease,Patients with unstable angina or history of thrombotic events
Hypersensitivity to vasopressin or components; anuria; chronic nephritis with nitrogen retention; cardiovascular disease (ischemic heart disease, advanced atherosclerosis, coronary thrombosis).
No significant food interactions. However, fluid intake should be carefully monitored to avoid water intoxication. Avoid excessive alcohol or caffeine intake, as they may interfere with antidiuretic effect.
Avoid excessive fluid intake beyond thirst to prevent water intoxication. Limit alcohol, which can inhibit vasopressin release and reduce drug efficacy. No specific food restrictions.
Desmopressin (DDAVP) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. There are no adequate and well-controlled studies in pregnant women. In human case reports, desmopressin use during pregnancy has not been associated with an increased risk of major birth defects, miscarriage, or adverse fetal outcomes. Theoretical risk of hyponatremia and seizures in the fetus if maternal hyponatremia occurs. Use during first trimester is generally considered low risk, but caution is advised. Second and third trimester: no specific fetal risks identified beyond those related to maternal hyponatremia.
PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossification at high doses. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Vasopressin may cause uterine contractions and decrease placental perfusion, potentially leading to fetal hypoxia or distress, particularly in the third trimester.
Desmopressin is excreted into breast milk in very low amounts. The M/P ratio is approximately 0.3. Based on limited data, oral desmopressin is considered compatible with breastfeeding. Intranasal and injectable formulations also likely safe due to low systemic absorption. Monitor infant for signs of water retention or hyponatremia (rare).
It is unknown whether vasopressin is excreted in human breast milk. Due to its high molecular weight (tannate salt) and poor oral bioavailability, significant absorption by a nursing infant is unlikely. However, caution is advised. No M/P ratio is available.
No standard dose adjustment required for desmopressin during pregnancy. However, increased renal clearance in pregnancy may reduce drug efficacy; if clinical response decreases, titrate dose upward based on urine output, thirst, and serum sodium. Monitor for uterine contractions with high doses (oxytocin-like effect occurs at supratherapeutic doses). Start at lowest effective dose and adjust as needed.
No specific dose adjustments are established for pregnancy. However, because of increased plasma volume and renal clearance during pregnancy, lower serum concentrations may occur. Individualize dosing based on clinical response and avoidance of adverse effects such as hyponatremia and hypertension. Use the lowest effective dose.
DDAVP (desmopressin) is a synthetic analog of vasopressin that does not require refrigeration, allowing for convenient storage and travel. It is available as oral tablets, nasal spray, and injectable forms. Monitor for hyponatremia, especially in elderly patients or those with fluid overload. Avoid use in patients with primary polydipsia or severe renal impairment. For nocturnal enuresis, limit fluid intake 1 hour before bedtime to reduce the risk of water intoxication. In hemophilia A or von Willebrand disease, DDAVP can transiently increase factor VIII and v WF levels; however, tachyphylaxis may occur after repeated doses.
Pitressin Tannate is an aqueous suspension of vasopressin for intramuscular injection used for diabetes insipidus. Must be warmed and shaken vigorously before administration to ensure uniform suspension. Inject deeply IM into a large muscle; do not administer IV or subcutaneously. Onset is within 1-2 hours, duration 24-72 hours. Monitor for signs of water intoxication (headache, confusion, seizures) due to antidiuretic effect. Caution in coronary artery disease, hypertension, and renal impairment. Discontinue if abdominal cramps or nausea occur. Not for use in chronic nephrogenic diabetes insipidus.
Store DDAVP at room temperature (below 77°F/25°C); it does not need refrigeration.,Avoid drinking large amounts of water or other fluids unless thirsty to prevent low sodium levels (hyponatremia).,Take the last dose at bedtime for bedwetting to reduce nighttime urine production.,Inform your doctor if you experience headache, nausea, confusion, or weight gain, as these may be signs of hyponatremia.,Do not change dosing or frequency without consulting your healthcare provider.
This medication is given as an injection into a muscle, usually every 1-3 days as prescribed.,Do not inject into a vein or under the skin; only into a muscle (buttock or thigh).,Warm the vial in your hands and shake it well just before use to mix the suspension evenly.,Drink only enough fluid to satisfy thirst; excessive fluid intake can lead to water intoxication.,Report any signs of water intoxication: severe headache, confusion, drowsiness, seizures, or difficulty breathing.,Avoid alcohol, which can interfere with the drug's effect and increase urine output.,Store the vial at room temperature away from light and do not freeze.,Monitor urine output and notify your doctor if it does not decrease or if side effects occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DDAVP (NEEDS NO REFRIGERATION) vs PITRESSIN TANNATE, answered by our medical review team.
DDAVP (NEEDS NO REFRIGERATION) is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.. PITRESSIN TANNATE is a Antidiuretic Hormone Analog that works by Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DDAVP (NEEDS NO REFRIGERATION) and PITRESSIN TANNATE depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DDAVP (NEEDS NO REFRIGERATION) is: 1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.. The standard adult dose of PITRESSIN TANNATE is: 0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DDAVP (NEEDS NO REFRIGERATION) and PITRESSIN TANNATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DDAVP (NEEDS NO REFRIGERATION) is classified as Category C. Desmopressin (DDAVP) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. There are no adequate and well-controlled studies in pr. PITRESSIN TANNATE is classified as Category C. PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossifi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.